Lay two or three companies' shapes over each other and see, axis by axis, which stands higher against its own sector.
| Axis | XOM | CVX |
|---|---|---|
| Profitability | - | 66 |
| Financial health | 74 | 74 |
| Growth | 88 | 38 |
| Insider conviction | - | 3 |
| Institutional and government | 50 | 50 |
| Risk and compliance | - | 90 |
| XOM | CVX | |
|---|---|---|
| Return on equity | - | +12.2% 64 pct |
| Return on assets | - | +7.1% 68 pct |
| Return on invested capital | - | - |
| Return on capital employed | - | - |
| XOM | CVX | |
|---|---|---|
| Debt to equity | 0.16x 74 pct | 0.21x 69 pct |
| Cash flow to debt | - | 1.13x 79 pct |
| XOM | CVX | |
|---|---|---|
| Revenue growth, YoY | +42.3% 88 pct | -4.6% 38 pct |
| Backlog growth, YoY | - | - |
| XOM | CVX | |
|---|---|---|
| Net open-market buying, 180d | - | -$346.6M 5 pct |
| Insider buyers, 180d | - | 0 0 pct |
| XOM | CVX | |
|---|---|---|
| Funds adding, latest quarter | 1,839 99 pct | 1,973 100 pct |
| Congress net buyers, 365d | -2 0 pct | -2 0 pct |
| Federal contracts, 180d | - | - |
| Lobbying spend, 4 quarters | - | - |
| XOM | CVX | |
|---|---|---|
| Short interest, % of float | - | +0.8% 90 pct |
| Product recalls, 3y | - | - |
| EPA enforcement cases, 5y | - | - |
| Risk-factor change, latest 10-K | - | - |
Every score is a percentile against the company's own sector peers. A missing axis is unmeasured, not a low score. Not a forecast and not advice.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-09-17 ·
For informational purposes only, not investment advice.
Privacy · Terms
No password to create and no card required. We store your email address and nothing else.